Clin Endosc.  2013 Jan;46(1):24-29. 10.5946/ce.2013.46.1.24.

Photodynamic Therapy (PDT): PDT Mechanisms

• Allison RR
• Moghissi K

• KMID: 1792636
• DOI: http://doi.org/10.5946/ce.2013.46.1.24

Abstract

Photodynamic therapy (PDT) is a light based therapy used to ablate tumors. As practiced in oncology a photosensitizing agent is applied and then activated by a specific wavelength and energy of light. This light energy in the presence of oxygen will lead to the creation of the photodynamic reaction which is cyto and vasculo toxic. This paper will review the mechanisms of action of PDT and how they may be manipulated to improve clinical outcome in cancer patients.

Keyword

Photochemotherapy; Mechanisms; Photosensitizing agents; Photodynamic reaction

MeSH Terms

Humans
Light
Oxygen
Photochemotherapy
Photosensitizing Agents
Triazenes
Oxygen
Photosensitizing Agents
Triazenes

Reference

1. Dougherty TJ, Gomer CJ, Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst. 1998; 90:889–905. PMID: 9637138.

2. Allison RR, Mota HC, Sibata CH. Clinical PD/PDT in North America: an historical review. Photodiagnosis Photodyn Ther. 2004; 1:263–277.

3. Lipson RL, Baldes EJ. The photodynamic properties of a particular hematoporphyrin derivative. Arch Dermatol. 1960; 82:508–516. PMID: 13762615.

4. Lipson RL, Baldes EJ. Photosensitivity and heat. Arch Dermatol. 1960; 82:517–520. PMID: 13762614.

5. Dougherty TJ. Photodynamic therapy (PDT) of malignant tumors. Crit Rev Oncol Hematol. 1984; 2:83–116. PMID: 6397270.

6. Allison RR, Downie GH, Cuenca R, Hu XH, Childs CJ, Sibata CH. Photosensitizers in clinical PDT. Photodiagnosis Photodyn Ther. 2004; 1:27–42.

7. Mang TS. Lasers and light sources for PDT: past, present and future. Photodiagnosis Photodyn Ther. 2004; 1:43–48.

8. Brancaleon L, Moseley H. Laser and non-laser light sources for photodynamic therapy. Lasers Med Sci. 2002; 17:173–186. PMID: 12181632.

9. Sibata CH, Colussi VC, Oleinick NL, Kinsella TJ. Photodynamic therapy in oncology. Expert Opin Pharmacother. 2001; 2:917–927. PMID: 11585008.

10. Moan J, Berg K. The photodegradation of porphyrins in cells can be used to estimate the lifetime of singlet oxygen. Photochem Photobiol. 1991; 53:549–553. PMID: 1830395.

11. Mroz P, Yaroslavsky A, Kharkwal GB, Hamblin MR. Cell death pathways in photodynamic therapy of cancer. Cancers. 2011; 3:2516–2539.

12. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci. 2002; 1:1–21. PMID: 12659143.

13. Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002; 2:277–288. PMID: 12001989.

14. Boyle RW, Dolphin D. Structure and biodistribution relationships of photodynamic sensitizers. Photochem Photobiol. 1996; 64:469–485. PMID: 8806226.

15. Hamblin MR, Newman EL. On the mechanism of the tumour-localising effect in photodynamic therapy. J Photochem Photobiol B. 1994; 23:3–8. PMID: 8021748.

16. Jori G, Reddi E. The role of lipoproteins in the delivery of tumour-targeting photosensitizers. Int J Biochem. 1993; 25:1369–1375. PMID: 8224351.

17. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part three: photosensitizer pharmacokinetics, biodistribution, tumor localization and modes of tumor destruction. Photodiagnosis Photodyn Ther. 2005; 2:91–106.

18. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part two: cellular signaling, cell metabolism and modes of cell death. Photodiagnosis Photodyn Ther. 2005; 2:1–23.

19. Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res. 1998; 150(5 Suppl):S146–S156. PMID: 9806617.

20. Ding X, Xu Q, Liu F, et al. Hematoporphyrin monomethyl ether photodynamic damage on HeLa cells by means of reactive oxygen species production and cytosolic free calcium concentration elevation. Cancer Lett. 2004; 216:43–54. PMID: 15500948.

21. Henderson BW, Donovan JM. Release of prostaglandin E2 from cells by photodynamic treatment in vitro. Cancer Res. 1989; 49(24 Pt 1):6896–6900. PMID: 2531034.

22. Henderson BW, Owczarczak B, Sweeney J, Gessner T. Effects of photodynamic treatment of platelets or endothelial cells in vitro on platelet aggregation. Photochem Photobiol. 1992; 56:513–521. PMID: 1454881.

23. Dahle J, Kaalhus O, Moan J, Steen HB. Cooperative effects of photodynamic treatment of cells in microcolonies. Proc Natl Acad Sci U S A. 1997; 94:1773–1778. PMID: 9050854.

24. Agarwal ML, Clay ME, Harvey EJ, Evans HH, Antunez AR, Oleinick NL. Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res. 1991; 51:5993–5996. PMID: 1933862.

25. Abels C. Targeting of the vascular system of solid tumours by photodynamic therapy (PDT). Photochem Photobiol Sci. 2004; 3:765–771. PMID: 15295633.

26. Chen B, Pogue BW, Goodwin IA, et al. Blood flow dynamics afterphotodynamic therapy with verteporfin in the RIF-1 tumor. Radiat Res. 2003; 160:452–459. PMID: 12968929.

27. Fingar VH, Wieman TJ, Doak KW. Role of thromboxane and prostacyclin release on photodynamic therapy-induced tumor destruction. Cancer Res. 1990; 50:2599–2603. PMID: 2139357.

28. McMahon KS, Wieman TJ, Moore PH, Fingar VH. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response. Cancer Res. 1994; 54:5374–5379. PMID: 7923168.

29. Krosl G, Korbelik M. Potentiation of photodynamic therapy by immunotherapy: the effect of schizophyllan (SPG). Cancer Lett. 1994; 84:43–49. PMID: 8076362.

30. Gollnick SO, Liu X, Owczarczak B, Musser DA, Henderson BW. Altered expression of interleukin 6 and interleukin 10 as a result of photodynamic therapy in vivo. Cancer Res. 1997; 57:3904–3909. PMID: 9307269.

31. Coutier S, Bezdetnaya L, Marchal S, et al. Foscan (mTHPC) photosensitized macrophage activation: enhancement of phagocytosis, nitric oxide release and tumour necrosis factor-alpha-mediated cytolytic activity. Br J Cancer. 1999; 81:37–42. PMID: 10487610.

32. Gollnick SO, Evans SS, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer. 2003; 88:1772–1779. PMID: 12771994.

33. Allison RR, Sibata CH. Photofrin photodynamic therapy: 2.0 mg/kg or not 2.0 mg/kg that is the question. Photodiagnosis Photodyn Ther. 2008; 5:112–119. PMID: 19356641.

34. Allison RR, Sibata CH. Photodiagnosis for cutaneous malignancy: a brief clinical and technical review. Photodiagnosis Photodyn Ther. 2008; 5:247–250. PMID: 19356664.

35. Hamblin MR, Rajadhyaksha M, Momma T, Soukos NS, Hasan T. In vivo fluorescence imaging of the transport of charged chlorin e6 conjugates in a rat orthotopic prostate tumour. Br J Cancer. 1999; 81:261–268. PMID: 10496351.

36. Kurohane K, Tominaga A, Sato K, North JR, Namba Y, Oku N. Photodynamic therapy targeted to tumor-induced angiogenic vessels. Cancer Lett. 2001; 167:49–56. PMID: 11323098.

37. Chen B, Roskams T, de Witte PA. Antivascular tumor eradication by hypericin-mediated photodynamic therapy. Photochem Photobiol. 2002; 76:509–513. PMID: 12462645.

38. Allison RR. Future PDT. Photodiagnosis Photodyn Ther. 2009; 6:231–234. PMID: 19932457.

39. Allison RR, Bagnato VS, Sibata CH. Future of oncologic photodynamic therapy. Future Oncol. 2010; 6:929–940. PMID: 20528231.